Denervation-Induced Skeletal Muscle Atrophy is Associated with Increased Mitochondrial ROS Production

Florian L. Muller², Wook Song², Youngmok C. Jang², Yuhong Liu², Marian Sabia¹, Arlan Richardson¹,²,³, and Holly Van Remmen¹,²,³

¹South Texas Veterans Health Care System, San Antonio, Texas 78284-7762, the ²Department of Cellular and Structural Biology and the ³Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900;

Running Title: Muscle atrophy, denervation and mitochondrial ROS

To whom correspondence should be addressed:
Holly Van Remmen, Ph.D.
Department Cellular and Structural Biology
University of Texas Health Science Center at San Antonio
Barshop Institute for Longevity and Aging Studies
15355 Lambda Drive Mail Code 7755
San Antonio, Texas 78245-3207
Fax: (210) 562-6141

E-mail: vanremmen@uthscsa.edu
Abstract

Reactive oxygen species (ROS), especially mitochondrial ROS, are postulated to play a significant role in muscle atrophy. We report a dramatic increase in mitochondrial ROS generation in three conditions associated with muscle atrophy: aging, in mice lacking CuZnSOD (Sod1\(^{-/-}\)), and in the neurodegenerative disease, Amyotrophic Lateral Sclerosis (ALS). Our data show ROS generation in muscle mitochondria is nearly 3-fold higher in 28- to 32-month-old than in 10-month-old mice, and is associated with a 30% loss in gastrocnemius mass. In Sod1\(^{-/-}\) mice, muscle mitochondrial ROS production is increased over 100% in 20 -month compared to 5-month-old mice along with a greater than 50% loss in muscle mass. ALS G93A mutant mice show a 75% loss of muscle mass during disease progression and up to 12-fold higher muscle mitochondrial ROS generation. In a second ALS mutant model, H46RH48Q mice, ROS production is ~4-fold higher than in control mice and is associated with a less dramatic loss (30%) in muscle mass. Thus, ROS production is strongly correlated with the extent of muscle atrophy in these models. Because each of the models of muscle atrophy studied here are associated to some degree with a loss of innervation, we were interested in determining if denervation plays a role in ROS generation in muscle mitochondria isolated from hind limb muscle following surgical sciatic nerve transection. Seven days post-denervation, muscle mitochondrial ROS production increased nearly 30-fold. We conclude that enhanced generation of mitochondrial ROS may be a common factor in the mechanism underlying denervation-induced atrophy.

Keywords: mitochondria, ROS, muscle atrophy, ALS, CuZnSOD, denervation
INTRODUCTION

Skeletal muscle atrophy is a debilitating phenotype that is associated with a variety of conditions, including neurodegenerative diseases, cancer cachexia, and immobilization or disuse (49, 56, 76, 77). Muscle atrophy is also an unavoidable consequence of normal human aging (43, 68). Despite the importance and impact of losing muscle mass, the biochemical and molecular mechanisms leading to muscle atrophy are still poorly understood. Several potential contributing factors in loss of muscle mass have been identified, including neuromuscular alterations, changes in protein synthesis and degradation, and loss of fibers due to apoptosis (15, 52, 58). Oxidative stress and mitochondrial dysfunction have also been implicated in sarcopenia (27, 62), hind limb unloading (3, 46, 65) and in atrophic mouse muscle from ALS transgenic mice (54). Because mitochondria are an important source of reactive oxygen species in cells, we were interested in delineating the role of muscle mitochondrial ROS generation in muscle atrophy. In this study, we measured mitochondrial ROS production during aging in wild type mice and in mutant mouse models associated with significant loss of muscle mass to assess the importance of ROS generation in the basic mechanism(s) underlying muscle atrophy.

The first muscle atrophy model we studied is a knockout mouse lacking a major antioxidant enzyme, CuZn-superoxide dismutase (Sod1^{-/-} mice, (67)). In a recent study, we reported that the Sod1^{-/-} mice show a dramatic age-related loss of skeletal muscle mass that is accelerated compared to wild type mice (57). By 20 months of age, the Sod1^{-/-} mice have lost nearly 50% of their hind limb muscle mass. The loss of mass is greatest in the gastrocnemius, while the soleus muscle is relatively spared. This is similar
to the pattern of muscle loss seen in wild type mice during aging, as muscles with high proportions of Type IIb fibers such as gastrocnemius are more susceptible to loss of mass than muscles with higher percentages of Type I oxidative fibers, such as the soleus (34). The Sod1−/− mice are also characterized by very high levels of oxidative stress and elevated levels of oxidative damage to lipid, protein and DNA in several tissues, including skeletal muscle mice (57).

The second type of mutant mouse model we used in this study is transgenic mice overexpressing mutant forms of CuZnSOD which are found in humans with the neurodegenerative disease, Amyotrophic Lateral Sclerosis (ALS). ALS is characterized by selective loss of upper and lower motor neurons, which ultimately leads to muscle atrophy, paralysis and death from respiratory failure (61). Transgenic mice expressing mutant forms of the CuZnSOD protein develop a disease strikingly similar to ALS (31) including paralysis and significant loss of muscle mass during the course of the disease and are extensively used as a model to study the disease. We measured ROS production in skeletal muscle mitochondria from two different CuZnSOD mutant mouse lines (G93A (31) and H46RH48Q (81)). Both of these mutant mouse lines exhibit paralysis and muscle atrophy during progression of the disease, but differ in the time course of disease progression and we report here for the first time, also differ in the extent and pattern of loss of muscle mass. In the G93A mutant mice, the first symptoms (tremor and muscle weakness) appear at approximately 90 days, and the disease reaches end stage, characterized by a dramatic loss of neurons (50%), at around 150 days (30). In the H46RH48Q mutant mice, the onset of the disease is later, at ~ 180 days of age, and the
mice die at ~240 days. In contrast to the G93A mutant mice, the H46RH48Q mice do not develop significant muscle atrophy until late in the course of the disease.

In this study, we propose that mitochondrial ROS is a critical factor in the mechanism underlying muscle atrophy. In agreement with our hypothesis, in all three models we observed a significant increase in ROS generation that correlated to the extent of muscle atrophy, i.e., greater ROS generation in models exhibiting greater atrophy. Because the atrophy that occurs in the three conditions we have studied (aging, Sod1/- mice, and in ALS) is largely the result of loss of innervation, we asked whether mitochondrial generation of ROS would be induced by surgical denervation. Indeed, transection of the sciatic nerve led to rapid muscle mass loss, and a dramatic increase in mitochondria ROS production. Thus, we have uncovered an important role for loss of innervation in the induction of skeletal muscle mitochondrial ROS generation, oxidative stress and loss of muscle mass.
EXPERIMENTAL PROCEDURES

Animals. The Sod1<sup>−/−</sup> mice used in this study were generated by Dr. Charles Epstein’s laboratory at the University of California San Francisco and are previously described (19, 35). The mice were maintained in the heterozygous state (Sod1<sup>+/−</sup>) and backcrossed with C57BL/6J females (Jackson Laboratory) for at least 12 generations. Two different ALS mouse models were employed. The widely used G93A mouse model [C57Bl/6J Tg (SOD1-G93A)1Gur/J mice(31)], was obtained from the Jackson Lab (Bar Arbor, Maine). The H46RH48Q mutant mouse [C57Bl/6J x C3H Tg (SOD1-H46RH48Q) mice (81), line 139] was kindly provided by Dr. David Borchelt (University of Florida, Gainesville). All mice were maintained under specific pathogen-free conditions and all procedures for handling animals in this study were reviewed and approved by the IACUC (Institutional Animal Care and Use Committee) of University of Texas Health Science Center at San Antonio and the IACUC of Audie L. Murphy Memorial Veterans Hospital.

Mitochondrial Isolation. Mitochondria were purified from whole hind limb skeletal muscle (with the exception of the sciatic nerve transection experiments, in which only the gastrocnemius, soleus and tibialis were used) according to Chappell and Perry (11, 20), as described previously (55). Hind limb skeletal muscle was excised, weighed, bathed in 150 mM KCl and placed in Chappell-Perry buffer with the protease nagarse. The minced skeletal muscle was homogenized and the homogenate was centrifuged for 10 minutes at 600xg with the supernatant then being passed through cheesecloth and centrifuged at 14,000xg for 10 minutes. The resulting pellet was washed once in modified Chappell-Perry buffer with 0.5% bovine serum albumin and once in modified Chappell-Perry
buffer without bovine serum albumin. Mitochondria were used immediately. Protein concentration was measured with the Bradford method.

Mitochondrial $H_2O_2$ release. Mitochondrial ROS production was measured with the Amplex Red-horseradish peroxidase method (Molecular Probes, Eugene, OR (85)). Horseradish peroxidase (HRP, 2 Units/ml) catalyses the $H_2O_2$-dependent oxidation of non-fluorescent Amplex Red (80 µM) to fluorescent resorufin red (85). Thirty seven Units (U)/ml CuZnSOD were added to convert all $O_2^{•−}$ into $H_2O_2$, a necessity since $O_2^{•−}$ reacts very rapidly with HRP and HRP-Compound I, resulting in underestimation of the actual rate of $H_2O_2$ production (5, 44). Therefore, our results reflect the sum of both superoxide and $H_2O_2$ production and are referred to as ROS rather than $H_2O_2$ production (55). Fluorescence was followed at an excitation wavelength of 545 nm, emission wavelength of 590 nm using a Fluoroskan Ascent type 374 multi-well plate reader (Labsystems, Helsinki, Finland). The slope of the increase in fluorescence is converted to the rate of $H_2O_2$ production with a standard curve. We performed all assays at 37°C, in 96-well plates. Substrates used were 5 mM succinate and 5 mM glutamate plus malate. For each assay, one reaction well contained buffer only and another contained buffer with mitochondria so as to estimate the background oxidation rates of Amplex red and to estimate the rate of $H_2O_2$ release in mitochondria without substrate (state 1) (9). The reaction buffer consisted of 125 mM KCl, 10 mM HEPES, 5 mM MgCl₂, 2 mM K₂HPO₄, pH 7.44.

Mitochondrial respiration. Mitochondrial oxygen consumption was measured using a Clark electrode ((83), Oxytherm, Oxygen electrode system from PP System, Hansatech Instruments Ltd.) as originally described by Estabrook (21). The respiratory buffer
consisted of 125 mM KCl, 10 mM HEPES, 5 mM MgCl₂, 2 mM K₂HPO₄, pH 7.44; with 0.3% BSA. State 3 respiration was induced with the addition of 0.3 mM ADP. 

*Denervation.* Sciatic nerve transection (47, 79) was performed on C57BL/6J females aged, 3 to 5 months. Animals were anesthetized using constant flow isoflurane inhalation anesthesia. In each hind limb (at the level of the femur) a small incision was made and the sciatic nerve was isolated. In the left leg the sciatic nerve was severed and a 5 mm section of sciatic nerve was removed. The ends of the nerve were folded back and sutured to prevent nerve re-growth. The right leg served as the control. The gastrocnemius, soleus and tibialis (muscles innervated by the sciatic nerve) were collected and used for analysis.

*Chemicals.* All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise specified.
RESULTS

*ROS production is increased in muscle mitochondria during aging and is correlated with muscle atrophy.* Our first set of experiments was designed to determine whether the age-related loss of muscle mass is associated with alterations in muscle mitochondrial ROS generation. Atrophy in skeletal muscle as a function of age in C57BL6 male mice was determined by measuring the mass of a representative muscle, the gastrocnemius. Gastrocnemius muscle mass was reduced nearly 13% at 28 months in male wild type mice and more than 40% at 32 months compared to 10-month-old adult control mice (Figure 1A).

ROS production and mitochondrial respiration were measured in muscle mitochondria isolated from 10-month, 28-month and 32-month-old mice. Figure 1B shows mitochondrial respiration expressed as the respiratory control ratio (RCR=State 3/State 4 respiration) in mitochondria isolated from muscle of old mice, 28 to 32 months of age. The RCR is decreased approximately 33 to 38% in mitochondria from the older mice.

Measurement of mitochondrial ROS production in isolated mitochondria is most traditionally done in the presence of added substrates, largely because the levels of ROS with endogenous (State 1) substrates are too low to detect. In a previous study, we demonstrated that the fluorogenic probe, Amplex Red is sensitive enough to detect ROS produced in mitochondria even during State 1, in the absence of exogenous substrates (10). In fact, we previously found that the age-related increase in State 1 ROS generation is greater than in mitochondria exposed to glutamate/malate or succinate as respiratory substrates (55). As shown in Figure 1C, State 1 ROS production was increased nearly 2-
fold in mitochondria isolated from hind limb skeletal muscle from 28-month-old male mice compared to mitochondria from 10-month-old mice. In 32-month-old animals, the increase in ROS generation was even greater, reaching levels ~3-fold higher than in 10-month-old control animals.

Glutamate/malate is a substrate that delivers electrons to Complex I of the mitochondrial electron transport chain, after which the electrons are transferred to ubiquinone, Complex III, Complex IV and ultimately oxygen (59, 69). In mitochondria isolated from muscle of 10-month-old mice, ROS generation was about 5 times higher with glutamate/malate than in State 1 without the addition of substrate. ROS generation in mitochondria respiring on glutamate/malate occurs primarily from electron transfer through Complex I, but there is also a contribution from Complex III (12, 32). ROS production using glutamate/malate was increased with age; and was approximately 40% higher in muscle mitochondria from 28- to 32-month-old mice compared to mitochondria from 10-month-old mice (Figure 1C). The difference in ROS production with 5 mM glutamate/malate as a substrate did not reach statistical significance (P<0.06 by ANOVA) when the aged (28 and 32 months old) animals were treated as independent groups, but did reach significance when the aged animals were combined (P<0.001 by ANOVA). When ROS generation with glutamate/malate was stimulated by the addition of the Complex I inhibitor, rotenone, the rate of ROS generation is increased approximately 10-fold but any effect of age disappeared (Figure 1D).

ROS release with the substrate succinate exhibited quite different trends from the results we obtained for State 1 and with glutamate/malate. Most studies indicate the highest rates of H$_2$O$_2$ release in isolated mitochondria are obtained with succinate as
substrate (32, 80)). \( \text{H}_2\text{O}_2 \) released under these conditions is derived from superoxide produced largely during reverse-electron transfer through Complex I (32, 33). Although the exact physiological significance of this phenomenon is unclear (2, 37), there is considerable interest in succinate driven reverse-electron transfer, because this source of ROS is so much greater than any others, at least under conventional conditions (see discussion in (32)) and in the absence of respiratory inhibitors (32, 80). We compared the rates of ROS generation in young and old skeletal muscle mitochondria with succinate as a substrate (Figure 1D), and found that there was no significant change with age, which is in general agreement with other studies that have investigated this question using similar methodology and conditions (32). The addition of the antimycin A, the Complex III inhibitor, resulted in a 7- to 8-fold increase in ROS generation that, similar to the production of ROS in response to the Complex I inhibitor rotenone, was not different with age.

Skeletal muscle mitochondrial ROS production is increased in \textit{Sod1} null mice and is associated with the degree of muscle atrophy. In agreement with our previous report on \( \textit{Sod}1^{-/-} \) mice (57), the gastrocnemius mass was significantly decreased in both young (5 month) and older (20 month) \( \textit{Sod}1^{-/-} \) mice compared to the age-matched wild type mice (Figure 2A). At 5 months, the mass of the gastrocnemius was approximately 25% lower than in wild type mice. At 20 months, the reduction in mass reaches approximately 50%. The wild type mice did not show any age-related loss in muscle mass between ages 5 and 20 months. As shown in Figure 2B, the RCR is decreased approximately 36% in
mitochondria isolated from muscle of 20 month old Sod1<sup>−/−</sup> mice compared to mitochondria from muscle of age-matched wild type mice.

State 1 ROS production was increased over 30% in mitochondria from Sod1<sup>−/−</sup> mice at as early as 5 months of age compared to age-matched, wild type mice (Figure 2C). By 20 months of age, ROS production in mitochondria from Sod1<sup>−/−</sup> mice was 3-fold higher than in the age-matched, wild type mice. In mitochondria incubated with glutamate malate as respiratory substrates, ROS release was increased about 35% (30.89±4.77 in mitochondria from 5-month-old Sod1<sup>−/−</sup> compared to 19.77±1.78 pmoles H<sub>2</sub>O<sub>2</sub>/min/mg protein in age-matched, wild type mice). In 20-month-old Sod1<sup>−/−</sup> mice, the increase in ROS generation with the substrates glutamate and malate was greater than 100% (Figure 2C). There was no significant difference in ROS production in State 1 or in response to glutamate/malate in mitochondria from the 20-month-old mice in either group as compared to the 5-month-old mice (Figure 2C). This is consistent with increased ROS being specifically associated with age-associated muscle loss, as wild type mice do not show any muscle mass loss at 20 months compared to the muscle mass at 5 months of age.

Somewhat unexpectedly, we found that mitochondrial H<sub>2</sub>O<sub>2</sub> release with the substrate succinate is significantly lower in mitochondria from the Sod1<sup>−/−</sup> mice compared to wild type controls, especially in mitochondria from the 20-month-old Sod1<sup>−/−</sup> mice (see Figure 2D). In mitochondria treated with glutamate/malate and the Complex I inhibitor rotenone, or with succinate and the Complex III inhibitor antimycin A, there was no difference between ages and genotypes (Figure 2D).
ROS production is increased in muscle mitochondria in mouse models of ALS and is correlated with the extent of muscle atrophy. We next measured State 1 ROS production in mitochondria in another mouse model associated with significant muscle atrophy, mice expressing mutant forms of CuZnSOD. We studied two different ALS mutant models, the well characterized G93A mutant (31) and mice generated using a metal deficient H46RH48Q (81) mutant that has no CuZnSOD activity. As shown in Figure 3, these models had very different patterns of loss of muscle mass during the progression of the disease. The muscle mass of the hind limb began to decrease as early as 60 to 70 days in the G93A mutants, even before visible symptoms occurred at the age of onset (Figure 3A, C). However, in the H46RH48Q mutant mice, the hind limb mass remained essentially unchanged until very late in the disease (Figure 3B, D). Even at the end stage of the disease (shortly before death) hind limb mass is decreased approximately 45% in H46RH48Q mice, which is comparable to what is observed in the early stages of the disease in the G93A mutants and in the 20-month-old (late stage) Sod1−/− mice. In contrast, late state G93A mice exhibited decreases in hind leg mass approaching 80%.

The pattern of muscle atrophy correlated closely with increases in mitochondrial ROS production. State 1 ROS release during the disease course in G93A mice is increased almost 10-fold above levels in the mitochondria from wild type mice, much higher than in the Sod1−/− mice or in old wild type mice, which had relatively less muscle atrophy. In the H46RH48Q mutant mice, there was an up to 4-fold increase in ROS release at late stage, but virtually no change at early symptomatic stage. In symptomatic-stage G93A mice, with glutamate/malate as respiratory substrate, ROS release is increased over 6-fold (Figure 4A), but in contrast, in the H46RH48Q, ROS release was only ~75% higher as
compared to wild type age-matched control (Figure 4D). As we had observed in mitochondria from the $Sod1^{-/-}$ mice, ROS production with succinate as a substrate was lower in G93A skeletal muscle mitochondria than in mitochondria from control mice, and showed an even greater decrease than had been observed in the $Sod1^{-/-}$ mice, approaching levels close to that measured in State 1 in the absence of substrate. As shown in Figure 4C, in addition the increase in ROS, the RCR is decreased 46% in mitochondria isolated from muscle of end stage G93A mice compared to age-matched wild type mice.

*ROS production is increased in muscle mitochondria following surgical denervation.* To determine whether denervation might be a factor in the increase in mitochondrial ROS in the three models of muscle atrophy studied here, we measured mitochondrial State 1 ROS generation in the gastrocnemius and tibialis anterior muscles, following denervation by surgical sciatic nerve transection. ROS release was increased dramatically 5 days after sciatic nerve transection, (Figure 5A). As shown in Figure 5B, at 7 days post-denervation, the loss of muscle mass was minimal, yet state 1 ROS production was nearly 30-fold higher in mitochondria isolated from the muscle in the denervated limb as compared to the contralateral control limb. ROS release with glutamate/malate was 11-fold higher in the muscle mitochondria from the denervated limb compared to the control limb (Figure 5C) at 7 days. There was no significant difference in the rates of ROS production in response to denervation using succinate or in the presence of the inhibitors of antimycin A and rotenone (data not shown). The RCR was decreased almost 30% in mitochondria isolated from the muscle in the denervated limb as compared to the contralateral control limb (Figure 5D).
The relationship between muscle trophy and induction of ROS generation by skeletal muscle mitochondria isolated from young and old wild type mice, 20 month old Sod1⁻/⁻ mice and the two ALS mouse models is illustrated in Figure 6. The plot clearly shows that models with a greater loss of muscle mass show relatively higher levels of ROS production.
DISCUSSION

The major finding of this study is that ROS production was elevated in skeletal muscle mitochondria isolated from mice representing three different conditions associated with significant loss of muscle mass: age related muscle atrophy, Sod1\(^{-/-}\) mice (a mouse model of accelerated sarcopenia), and two ALS mutant mouse models differing in the time course and extent of muscle mass loss during the progression of the disease. Thus, as Figure 6 illustrates, ROS production was lowest during normal aging (where the extent of muscle atrophy is lowest), higher in muscle from the Sod1\(^{-/-}\) mice, and increased nearly 10-fold in G93A ALS mutant mice that showed the most dramatic muscle atrophy. This relationship also holds within each of models studied, i.e., both ROS production and loss of muscle mass were higher in 32-month-old mice than in 27-month-old normal mice, ROS production and atrophy were higher in 20-month-old than in 5-month-old Sod1\(^{-/-}\) mice and ROS generation was higher in the G93A compared to the H46RH48Q mutant ALS models and in agreement with more atrophy in G93A.

Each of these three conditions has previously been reported to involve alterations in innervation of skeletal muscle. Innervation is critical for growth and maintenance of muscle fibers and denervation is well known to cause muscle atrophy (36). Denervation is extensively documented in ALS, being caused by the degeneration of lower motorneurons (75) while independent lines of evidence also attest to denervation (caused by breakdown of neuromuscular junctions) in Sod1\(^{-/-}\) mice (25, 57, 70). With respect to aging, it is understood that sarcopenia is a multifactorial process, and that denervation plays a significant role (15, 23). During normal aging, there is a loss of motor neurons in the spinal cord, a breakdown of neuromuscular junctions, and axonal sprouting is also
impaired (22, 78). Thus, one common characteristic of the three models (aging, Sod1−/−
mice, and ALS mutant mice) is alterations in innervation of muscle fibers (8, 24-26, 41, 67, 70). To test whether denervation contributes to an increase in mitochondrial ROS, we measured ROS generation in mouse muscle following sciatic nerve transection. ROS generation was dramatically increased in surgically denervated muscle, demonstrating a direct role for denervation in increased muscle mitochondrial ROS production. Thus, an elevation in ROS generation is a common event in skeletal muscle mitochondria under a variety of pathological conditions associated with denervation-induced muscle atrophy.

What is the connection between denervation and altered mitochondrial ROS generation? One potential factor may be a loss of trophic support to the muscle following denervation. Motor neurons are known to exert a trophic effect on skeletal muscle, and in the absence of neural activity, muscle mass decreases, along with a reduction in specific force, fiber diameter and fiber number (6, 73). Loss of motor neurons, breakdown of neuromuscular junctions or inhibition of neural signaling, occurs in many neuromuscular diseases including ALS or spinal cord injury (75), spinal muscular atrophy (56), diabetic neuropathy (72), and aging (6, 41, 48), and each of these situations is associated with muscle atrophy. It is possible that lack of trophic factors could have a negative impact muscle mitochondrial function. Another potential factor linking altered mitochondrial function and denervation is altered calcium handling. Denervation decreases calcium retention capacity in muscle mitochondria, resulting in an overall increase in calcium content in both mitochondria and whole muscle (14). Calcium is a key inducer of the permeability transition pore that regulates mitochondria–mediated cell death; therefore, altered regulation of calcium following denervation can lead to
induction of denervation-induced atrophy (71, 74). It is important to consider that while
the initiating event is likely a loss of innervation that leads to muscle mitochondrial
dysfunction, increased ROS generation and an increase in oxidative stress, the
consequences of these events may produce a positive feedback of oxidative damage that
in turn damages additional neurons or neuromuscular junctions, exacerbating the increase
in muscle ROS generation even further and continuing the cycle of damage.

Mitochondrial alterations have been reported in previous studies using sciatic nerve
 crush or nerve transection in rodents (1, 38, 39). For example, genes encoding the
mitochondrial respiratory chain and the TCA cycle are significantly downregulated
following denervation (48, 60, 66), and the levels of cytochrome c oxidase, succinate
dehydrogenase, citrate synthase, and cardiolipin are significantly lowered 8-14 days after
denervation (18, 82). Furthermore, as mentioned above, mitochondria may play a role in
muscle atrophy through induction of apoptosis in response to denervation (71). A recent
study in rats subjected to nerve transaction also reported an increase in mitochondrial
ROS generation that was associated with an increase in the mitochondrial permeability
transition and increased apoptosis (1). Together, these studies point to mitochondrial
dysfunction following denervation.

How might the increase in mitochondrial ROS production contribute to the loss of
muscle mass? Growing evidence implicates oxidative stress as an important regulator of
pathways leading to muscle atrophy (27, 36, 65). We can propose several ways that
mitochondrial ROS generation might contribute to muscle atrophy. It is possible that the
increased in ROS directly or indirectly damages proteins increasing their turnover which
could contribute to the increase in protein turnover observed after denervation.
Alternatively, increased ROS may damage critical enzymes, such as those involved in energy metabolism (45, 51). In fact, increased ROS production following denervation is mirrored by decreases in surface hydrophobicity and enzymatic activity of glyceraldehyde-3-phosphate dehydrogenase and creatine kinase (64)) possibly due to increased oxidative damage (63). Increased mitochondrial ROS may also play a signaling role. Another good candidate for an effect of ROS on signaling is NF-κB. NF-κB is known to play a role in muscle atrophy (7, 42) and it is well established that its transcriptional activity can be modulated by H$_2$O$_2$ (84). Mitochondria are known to play a central role in intrinsic pathway of apoptosis, and mitochondrial ROS generation and atrophy could also be linked through apoptosis (1, 29, 40). Mitochondrial ROS has also been shown to lead to upregulation of the expression of ubiquitin ligase, Atrogin-1/MAFbx (53) and could therefore contribute to atrophy through increased degradation of proteins by the 26S proteasome system.

One question that arises is whether the loss of innervation precedes the increase in mitochondrial ROS generation or vice versa. Based on our experiments in young and old wild type mice, the Sod1$^{-/-}$ model and the ALS mouse models, we cannot be certain whether the increase in ROS generation precedes or follows changes in innervation, especially in the Sod1$^{-/-}$ mice and in the case of aging, in which the changes occur over a very long time-frame (months). What is clear, however, is that in each situation, both muscle atrophy and ROS production increase over time. In ALS mice, muscle atrophy occurs over weeks rather than months and in this case it is possible to at least roughly correlate the timing of loss of muscle mass and ROS increase. In fact, it has been previously reported that denervation begins as early as 30 to 40 days of age in G93A ALS
mice (24). At this early phase of the disease, we already detect a small but significant increase in ROS production, supporting the fact that denervation and muscle ROS generation are closely related and suggesting denervation precedes the increase in ROS. Overall, our denervation experiments provide the strongest evidence regarding this issue. ROS generation is significantly increased after 2 days post nerve transaction, but not at 2 days post transection. This is strong evidence that the loss of innervation precedes the increase in muscle mitochondrial ROS generation. Furthermore, the sciatic nerve transection demonstrates that an elevation in ROS generation precedes a significant loss in muscle mass (by a few days or so). While ROS production is increased as early as 5 days after sciatic nerve transection, loss of muscle mass is evident at 7 days. The fact that dramatic changes in ROS are present before the loss of muscle mass supports the hypothesis that ROS may in fact contribute to muscle mass loss.

We unexpectedly found that the degree and dynamics of muscle mass loss where quite different in these two ALS animal models and that these changes correlated with muscle mitochondrial ROS generation. While denervation and muscle mass loss in the G93A was evident even before the onset of symptoms (24, 26), (in full agreement with our data in Figure 4), in the H46RH48Q, the extent of muscle mass loss was not only lower but also occurred very late in the disease course (Figure 4). In effect, the H46RH48Q mice developed ALS despite remarkably little muscle mass loss. Incidentally, ALS patients with the H46R mutation have a very long survival (4). The different patterns of muscle atrophy in the G93A and H46RH48Q mutants provide insight into the role of denervation in the etiology of ALS. ALS has been proposed to be more than a strict neuropathy, that is, skeletal muscle pathology might play an integral part in
the disease (16, 17, 54). A converging line of argument suggests that ALS is a distal axonopathy (24), that is, the disease starts at the neuromuscular junction and follows a dying-back pattern. The view that peripheral degeneration is central to the disease is gaining more widespread acceptance (28). However, virtually all of these observations were made in the G93A mice. The fact that H46RH48Q mice develop ALS with only mild muscle mass loss (and that occurs after disease onset) indicates that denervation is unlikely to be a major factor in disease etiology. While resolving these argument is beyond the scope of this paper, the relevant point remains that muscle mass loss is considerably less in the H46RH48Q as compared to the G93A, which is reflected in the extent of the elevation of ROS production.

Another interesting observation from our experiments is the finding that while muscle atrophy is associated with significant increases in mitochondrial ROS production in State 1 and with the substrates glutamate and malate, the exact opposite occurs with the substrate succinate; succinate-supported ROS release was significantly decreased in conditions in which the loss of muscle mass and loss of innervation were significant. For example, while there is no statistically significant difference in succinate supported ROS release with age, succinate-supported H₂O₂ release was in fact lower in old Sod1⁻/⁻ and late stage G93A ALS skeletal muscle mitochondria, conditions that are associated with losses in muscle mass greater than 50%. The mechanism(s) driving this decrease in ROS production and the potential physiological relevance of this phenomenon are not clear at this time. H₂O₂ formation with succinate is mostly due to reverse-electron transfer through Complex I (13, 33, 50), and the physiologic relevance of reverse-electron transfer is not certain. It has been suggested that succinate-driven reverse electron
transfer is likely an isolation artifact that only occurs at concentrations of succinate that are far higher as those found under normal in vivo conditions (32). We therefore conclude that the increases in ROS observed in State 1 which occur in the presence of endogenous substrate and with glutamate/malate represent the more physiologically relevant situations.

In summary, we report for the first time that several conditions associated with muscle atrophy and loss of innervation are associated with dramatic increases in mitochondrial production of ROS. Further studies are needed to determine the nature of the link between loss of innervation and mitochondrial dysfunction and the downstream targets and effects of the increase in mitochondrial ROS. A better of understanding of how these factors intact may be instrumental in leading to discovery and use of therapeutic interventions to delay or prevent muscle atrophy associated with alterations in neuromuscular interaction.
Figure Legends.

Figure 1. Increased ROS generation in skeletal muscle mitochondria from young and old mice. Skeletal muscle mitochondria were isolated and mitochondrial ROS generation was measured as described in EXPERIMENTAL PROCEDURES. The extent of age-related muscle atrophy was assessed by measuring the mass of the gastrocnemius muscle in male wild type mice at 10, 28 and 32 months (shown in Panel A). * denotes a significant difference compared to the 10-month adult control value (p<0.05, ANOVA with Tukey’s post hoc). Panel B shows mitochondrial respiration (RCR) measured in the presence of glutamate/malate as respiratory substrate in isolated muscle mitochondria from six 10 month, twelve 28 -29 month and eight 32 month old mice. The data in Panels C and D show the mean (± SEM) rates of mitochondrial ROS release. Panel C shows the values measured in male mice sacrificed at 10 months (white bars, n=6), 28 months (light grey bars, n=6), and 32 months of age (black bars, n=4) in the absence of exogenous substrate (State 1) and in the presence of 5 mM glutamate/malate. Panel D shows ROS production measured in the presence of 5 mM succinate alone, or with the substrates glutamate and malate or succinate in the presence of inhibitors of Complex I (rotenone) or Complex III (antimycin A). * indicates a statistically significant difference from the young wild type value (p<0.001, ANOVA with Tukey’s post-hoc).

Figure 2. Increased ROS generation in skeletal muscle mitochondria from Sod1^{−/−} mice. Panel A shows the mass of the gastrocnemius muscle isolated from female wild type and Sod1^{−/−} mice, at 5 and 20 months of age. Panel B shows mitochondrial
respiration (RCR) measured in the presence of glutamate/malate as respiratory substrate in isolated muscle mitochondria from eight wild type and eight Sod1−/− mice at 20 months of age. In all panels, white bars represent 5 months old wild type, hatched grey bars represent 5-month-old Sod1−/−, dark grey bars represent 20-month-old wild type and black hatched bars represent 20-month-old Sod1−/−. The data in Panels C and D represent the mean values ± SEM for ROS generation from skeletal muscle mitochondria isolated from the hind limb of the same group of mice. State 1 and glutamate/malate supported ROS generation in mitochondria from 5-month-old wild type mice (n=21; white bars), 5-month-old Sod1−/− mice (n=10; hatched grey bars), 20-month-old wild type (n=16; dark grey bars) and old Sod1−/− mice (n=16; hatched black bars) are shown in Panel C. Panel D shows ROS generation in the presence of succinate alone, antimycin A + succinate or glutamate/malate + rotenone. * denotes a significant difference in H2O2 release in muscle mitochondria from Sod1−/− mice compared to mitochondria from age-matched wild type mice (p<0.05, ANOVA with Tukey’s post hoc).

Figure 3. Muscle mass loss during ALS in the G93A and H46RH48Q mice. Hind limb muscle from female G93A (Panel A, black diamonds) or H46RH48Q (Panel B, grey diamonds) as well as non-transgenic, wild type control mice (white squares) was collected at the ages indicated and the mass is expressed in mg (Top, A, B) or relative to body mass (Bottom, C, D). The arrow denotes the onset of the disease in each mutant.

Figure 4. Increased ROS generation in skeletal muscle mitochondria isolated from ALS transgenic mice. ROS production was measured in skeletal muscle mitochondria
of female ALS transgenic mouse models G93A (Figure 4 A and B) and H46R/H48Q (Figure 3D). The data in Figure 4 (A) and (B) show the mean ± SEM for 12 wild type control and age-matched G93A transgenic mice (100 to 140 days of age). The data in Figure 4(D) represent the mean ± SEM for 5 wild type control and age-matched H46R/H48Q mice (200 to 240 days of age). * denotes a significant difference in H$_2$O$_2$ release from control in State 1 or with glutamate/malate as substrates (ANOVA, P<0.001). Panel B shows mitochondrial respiration (RCR) measured in the presence of glutamate/malate as respiratory substrate in isolated muscle mitochondria from ten wild type and ten end stage G93A mice. The time course of H$_2$O$_2$ generation in State 1 is shown in Figure 4E. ROS production was measured in mitochondria isolated from hind limb muscle of G93A (left panel) or H46R/H48Q transgenic mice (right panel) and wild type littermate mice at various stages during the lifespan of the mice. Filled symbols show values measured in mitochondria isolated from G93A mice and H46R/H48Q mice. Open triangles and open diamonds denote values measured in wild type (non-transgenic) mice, used as controls for the G93A mice and H46R/H48Q mice, respectively. Note the difference in magnitude of the response.

Figure 5. **ROS production is dramatically increased following surgical denervation.**

Denervation was introduced by surgical transection of the sciatic nerve at the level of the upper femur. The contralateral limb served as a control. Mice were sacrificed, tissues harvested, and ROS production was measured in isolated muscle mitochondria at 2 days (n=4), 5 days (n=5), 7 days (n=6), and 14 days (n=8) after surgery. The time course of the rate of ROS production in state 1 following denervation is shown in Panel A (denervated
muscle, black squares). The time course of muscle mass loss, measured as a ratio of weight of the gastrocnemius from the denervated and control legs, is shown in Panel B. Panel C shows the generation of ROS in mitochondria from the control (white bars) and denervated muscle (black bars) 7 days following denervation. Data shown in panel C is the mean values ± SEM for n=5. * denotes a significant difference in ROS generation in muscle mitochondria following denervation compared to mitochondria from control muscle (p<0.05, ANOVA with Tukey’s post hoc). Panel D shows mitochondrial respiration (RCR) measured in the presence of glutamate/malate as respiratory substrate in isolated muscle mitochondria from 28 wild type mice 7 days post sciatic nerve transection.

Figure 6. Correlation between muscle atrophy and ROS production. ROS production data in State 1 is plotted versus gastrocnemius muscle mass. Muscle mass and ROS production are expressed as a fold increase relative to young wildtype control values values. All values with exception of the 28 and 32 month old wildtype represent data collected in female mice. Because the mass of the gastrocnemius is always higher in males, the data from the 28 and 32 month old male mice are marked in open symbols.
ACKNOWLEDGEMENTS

We would like to thank the expert technical assistance of Amanda Jernigan and Jay Cox and editing expertise of Corinne Price. Financial support was provided by NIA training grant #5T3-AG021890-02 (FLM), P01 AG20591 (HVR, AR), Muscular Dystrophy Association grant # MDA3879 (HVR) and MERIT grant from the Department of Veterans Affairs (HVR).
CITED REFERENCES

17. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, and Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a


83. Williams MD, Van Remmen H, Conrad CC, Huang TT, Epstein CJ, and Richardson A. Increased oxidative damage is correlated to altered mitochondrial


Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.